Billiontoone, Inc. (NASDAQ:BLLN) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Key Points

• Moderate Buy consensus from 10 analysts (6 buys, 3 holds, 1 sell) with an average 12‑month price target of $126.71, though several firms have recently cut targets or issued mixed ratings.
• Quarterly beat: BillionToOne reported $0.11 EPS vs. $0.04 expected and $96.05M revenue (up 113% YoY), but the stock trades at a high P/E of 351 and opened recently at $73.71 after a 5.8% drop.
• Significant institutional buying: large new stakes were disclosed from Adams Street Partners (~$140M), Baillie Gifford (~$103.8M), Price T. Rowe (~$39.7M) and others, signaling notable investor interest.

Billiontoone, Inc. (NASDAQ:BLLN - Get Free Report) has been given an average rating of "Moderate Buy" by the ten ratings firms that are currently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and six have assigned a buy recommendation to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $126.7143.

A number of research analysts have recently weighed in on the company. Weiss Ratings started coverage on Billiontoone in a research note on Tuesday, February 3rd. They issued a "sell (d)" rating on the stock. Wall Street Zen raised Billiontoone from a "hold" rating to a "buy" rating in a research note on Saturday, March 7th. BTIG Research dropped their price objective on Billiontoone from $160.00 to $140.00 and set a "buy" rating on the stock in a research note on Thursday, March 5th. Wells Fargo & Company dropped their price objective on Billiontoone from $110.00 to $90.00 and set an "equal weight" rating on the stock in a research note on Thursday, March 5th. Finally, Guggenheim dropped their price objective on Billiontoone from $120.00 to $100.00 and set a "buy" rating on the stock in a research note on Monday, March 30th.

Billiontoone Stock Down 5.8%

BLLN stock opened at $73.71 on Thursday. The company has a fifty day moving average of $77.74. The company has a debt-to-equity ratio of 0.12, a quick ratio of 11.32 and a current ratio of 11.69. The firm has a market cap of $3.39 billion and a P/E ratio of 351.00. Billiontoone has a twelve month low of $61.96 and a twelve month high of $138.70.

Billiontoone (NASDAQ:BLLN - Get Free Report) last posted its quarterly earnings results on Wednesday, March 4th. The company reported $0.11 earnings per share for the quarter, beating analysts' consensus estimates of $0.04 by $0.07. The company had revenue of $96.05 million during the quarter, compared to analyst estimates of $85.85 million. Billiontoone's quarterly revenue was up 113.0% on a year-over-year basis. Research analysts anticipate that Billiontoone will post 0.42 earnings per share for the current fiscal year.

Institutional Trading of Billiontoone

Several hedge funds have recently added to or reduced their stakes in BLLN. Adams Street Partners LLC acquired a new stake in Billiontoone during the 4th quarter worth $140,063,000. Baillie Gifford & Co. acquired a new stake in Billiontoone during the 4th quarter worth $103,786,000. Price T Rowe Associates Inc. MD acquired a new stake in Billiontoone during the 4th quarter worth $39,717,000. JPMorgan Chase & Co. acquired a new stake in Billiontoone during the 4th quarter worth $32,078,000. Finally, Wasatch Advisors LP acquired a new stake in Billiontoone during the 1st quarter worth $29,179,000.

Billiontoone Company Profile

BillionToOne NASDAQ: BLLN is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.